12797 Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial

Subjects

Subjects :

medicine.medical_specialty
business.industry
Fixed-dose combination
Urology
Betamethasone dipropionate
Dermatology
medicine.disease
law.invention
Randomized controlled trial
law
Psoriasis
Calcipotriene
medicine
In patient
business
medicine.drug

Details

ISSN :

01909622

Volume :

83

Database :

OpenAIRE

Journal :

Journal of the American Academy of Dermatology

Accession number :

edsair.doi...........6f32254ff55f36334e4bb9dee470b0ed

Full Text :

https://doi.org/10.1016/j.jaad.2020.06.091